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Dear Editor,
A 22-year-old male presented in late 2015 with cough,
fatigue, and weight loss. Chest x-ray showed large peri-
cardial effusion, and chest CT confirmed the presence of a
large anterior mediastinal mass (15.7 × 19.4 × 9.7 cm).
Peripheral smear showed numerous blasts, and flow cy-
tometry showed the blasts had a T cell immunophenotype
with CD5, CD7, CD3, and TdT positivity. Bone marrow
biopsy was consistent with T-lymphoblastic leukemia; mi-
croscopic examination of the core biopsy revealed a
hypercellular marrow (approximately 90%) with predom-
inantly blasts. Cytogenetic studies were normal.
Treatment was initiated per augmented Berlin-Frankfurt-
Munster (BFM) pediatric protocol, and he achieved remis-
sion after induction with subsequent negative testing for
MRD. He received PEG-asparaginase as part of this reg-
imen and after the third dose developed nausea and thumb
tingling. His fibrinogen was low at 59 mg/dL (reference
range 151–402 mg/dL), and he received one unit of
cryoprecipitate. Two weeks later, he woke up with left
arm numbness and tingling followed by a 2-min general-
ized tonic-clonic seizure and left-sided weakness. Brain
MRI demonstrated superior sagittal sinus thrombosis with
right superior frontal hemorrhagic venous infarct (Fig. 1).
His fibrinogen was low at 77 mg/dL, and he received
cryoprecipitate, which was followed by antithrombin
(AT) concentrate (AT level 57%, reference range 83–
128%) and then heparin infusion. Fibrinogen was checked
twice a day with goal of >150 mg/dL. AT was checked
every 12 h with a goal of 80%. The heparin infusion was
continued for 3 days before transitioning to apixaban
(10 mg twice a day to complete a 7-day load, followed
by 5 mg bid).
MRI of the brain was repeated 2 months later and
showed resolution of the parenchymal edema and the su-
perior sagittal sinus thrombosis. No new dural venous
sinus thrombosis was present (Fig. 2). Now, 9 months
after his initial presentation, he remains on apixaban with-
out any further neurologic episodes and no major or
minor bleeding. He remains in remission and is being
treated in maintenance.
The augmented BFM protocol has been utilized in the
treatment of children with ALL [1] and has been shown to
have efficacy in adults as well [2]. In fact, it has been
shown to significantly improve outcomes in young adults
such as our patient [3]. Asparaginase is a critical compo-
nent of the regimen and improves outcomes [4–7].
Asparaginase impairs protein synthesis causing reduced
plasma levels of coagulation factors fibrinogen, factor
(F) V, FVII, FVIII, FIX, FX, FXI, and α2-antiplasmin
[8]. This increased bleeding risk is balanced by impair-
ment in the production of anticoagulant proteins anti-
thrombin, protein C, protein S, and plasminogen.
Fibrinogen and FVII recovery take place earlier than the
recovery of the anticoagulant proteins, and one of the
known toxicities of asparaginase is thrombus. The Dana-
Farber Cancer Institute [9] found that of 548 patients with
ALL treated with some form of asparaginase, and 9% of
pat ients aged 20–30 years developed a venous
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thromboembolism (VTE). Two of the 18 adult patients
who had VTE had sinus venous thrombosis.
Treatment of asparaginase-related VTE has historically
been with heparin or low molecular weight heparin
(LMWH). Our patient was treated with a heparin infusion
for 3 days, before transitioning to the anti-factor Xa agent
apixaban. Long-term recommendations for treatment in-
clude LMWH or warfarin. Given the efficacy of apixaban
in treating venous thromboses and the low bleeding risk
associated with its use when compared to warfarin [10,
11], we opted to treat our patient with apixaban rather
than LMWH or warfarin. To our knowledge, this is the
first report of the successful treatment with apixaban of a
thrombosis associated with PEG-asparaginase administra-
tion. Our patient has had an excellent clinical outcome,
with resolution of both his neurologic symptoms and ve-
nous thrombosis. Further testing of apixaban use in this
setting is warranted.
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